Prostaglandin D(2) induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig.

Larsson Callerfelt, Anna-Karin; Hagfjärd, Annika; Dahlén, Sven-Erik; Adner, Mikael

Published in:
European Journal of Pharmacology

DOI:
10.1016/j.ejphar.2011.07.046

2011

Link to publication

Citation for published version (APA):

Total number of authors: 4

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Prostaglandin D$_2$ induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig

Anna-Karin Larsson a,b*, Annika Hagfjärd a, Sven-Erik Dahlén a and Mikael Adner a

a Experimental Asthma and Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, b Lung Biology, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden

E-mail addresses:
Anna-Karin.Larsson@med.lu.se
Annika.Hagfjard@gmail.com
Sven-Erik.Dahlen@ki.se
Mikael.Adner@ki.se

*Corresponding author:
Anna-Karin Larsson, Lung Biology, Department of Experimental Medical Science, BMC D12, Lund University, 221 84 Lund, Sweden. Tel: +46 462229441
E-mail: Anna-Karin_L.Larsson@med.lu.se
Abstract

Prostaglandin D$_2$ (PGD$_2$), released through mast cell activation, is used as a non-invasive biomarker in patients with asthma. Since PGD$_2$ can elicit opposing effects on airway tone via activation of the PGD$_2$ receptors DP$_1$ and DP$_2$ as well as the thromboxane receptor TP, the aim of this study was to characterize the receptors that are activated by PGD$_2$ in the guinea pig lung parenchyma. PGD$_2$ and the thromboxane analogue U46619 induced concentration-dependent contractions. U46619 was more potent and caused stronger effect than PGD$_2$. The specific TP receptor antagonist SQ-29548 and the combined TP and DP$_2$ receptor antagonist BAYu3405 concentration-dependently shifted the curves for both agonists to the right. The DP$_1$ receptor agonist BW245 induced a weak relaxation at high concentrations, whereas the DP$_1$ receptor antagonist BWA868C did not affect the PGD$_2$ induced contractions. The specific DP$_2$ receptor agonist 13,14-dihydro-15-keto -PGD$_2$ showed neither contractile nor relaxant effect in the parenchyma. Furthermore, studies in precision-cut lung slices specified that airways as well as pulmonary arteries and veins contracted to both PGD$_2$ and U46619. When the lung parenchyma from ovalbumin sensitized guinea pigs were exposed to ovalbumin, both thromboxane B$_2$ and PGD$_2$ were released. Ovalbumin also induced maximal contractions at similar level as PGD$_2$ in the parenchyma, which was partly reduced by SQ-29548. These data show that PGD$_2$ should be recognized as a TP receptor agonist in the peripheral lung inducing contraction on airways, arteries and veins. Therefore, a TP receptor antagonist can be useful in combination treatment of allergic responses in asthma.

Keywords: Guinea pig; lung parenchyma; ovalbumin; precision cut lung slices; prostaglandin D$_2$; thromboxane
1. Introduction

Prostaglandin D$_2$ (PGD$_2$), secreted during mast cell activation (Dahlen and Kumlin, 2004), and its metabolite 9α-11β PGF$_{2α}$ are used as a non-invasive biomarkers in patients with asthma (O'Sullivan et al., 1996). PGD$_2$ is part of the acute asthmatic airway response; levels of this mediator can be found within minutes in BAL fluid and at 150-fold higher biologically active levels than before the exacerbation (Liu et al., 1991). In addition to the acute reaction, PGD$_2$ has through recruitment of inflammatory cells been suggested to contribute to the formation of the chronic asthmatic inflammation and subsequent airway remodelling (Balzar et al., 2011).

PGD$_2$, generated from arachidonic acid, is converted to PG via cyclooxygenase (COX) (Vane, 1971) and PGD synthase (Urade and Eguchi, 2002). There are two distinct types of PGDS; hematopoietic (H-PGDS) and lipocalin-type (L-PGDS). H-PGDS is highly expressed in mast cells, eosinophils, macrophages, and lymphocytes as well as structural cells such as epithelial cells and fibroblasts, whereas L-PGDS is mainly expressed in the central nervous system and heart (Okano et al., 2006). PGD$_2$ exits the cell via a carrier-mediated process and activates specific G-protein coupled receptors on target cells. PGD$_2$ is classified to mediate its effect via the DP$_1$ (Coleman et al., 1994) and the DP$_2$ (CRTH$_2$) receptors (Abe et al., 1999), but also known to act via the receptor for tromboxane A$_2$ (TXA$_2$), the TP receptor (Hamid-Bloomfield et al., 1990). The DP$_1$ receptor is widely distributed in airway and vascular smooth muscle, blood platelets, airway epithelium and nervous tissue (Coleman et al., 1994; Matsuoka et al., 2000; Norel et al., 1999). PGD$_2$ has also an important chemotactic role via activation of the DP$_2$ receptor (Abe et al., 1999), which is mainly expressed on Th2 cells and eosinophils (Abe et al., 1999) but also on human airway smooth muscle (Abe et al., 1999; Parameswaran et al., 2007). The TP receptors are expressed on bronchial and vascular smooth muscle cells, blood
platelets and myofibroblasts (Capra et al., 2003; Coleman et al., 1994) and are known to mediate a strong and long-lasting contraction in these tissues (Held et al., 1999; Ressmeyer et al., 2006). PGD$_2$ may thus have broad actions since activation of multiple receptors can elicit theoretically opposing effects on airway tone.

Although the lung parenchyma is a complex tissue, the action in the peripheral lung is of importance to study since asthma is suggested to be a disease of the small airways (van den Berge et al., 2011). Especially the action of PGD$_2$ is of interest since it has been shown that mast cells are located peripherally around small bronchi, vessels and further out to the alveoli (Andersson et al., 2009) and thus may not only affect airways. The aim of this study was therefore to characterize the receptors that are activated by PGD$_2$ in the peripheral lung and subsequently investigate the significance of this effect in allergen-induced contractions. The guinea pig parenchyma is particularly suitable as it has been shown to respond to many agonists similar to human (Canning and Chou, 2008; Ressmeyer et al., 2006).
2. Methods

2.1. Animals and ovalbumin-sensitization

Male Dunkin Hartley guinea pigs (300–350 g b.w.) were used. In one part of the experiments the guinea pigs were sensitized to ovalbumin at least four weeks prior to experiments as previously described (Larsson et al., 2005). The study was approved by the regional committee of animal experimentation ethics (N127/04, N63/07).

2.2. Lung parenchymal strips and organ bath experiments

The animals were sacrificed by an overdose of inhaled CO\(_2\) and the heart-lung-package was quickly removed and placed in ice-cold Tyrode's solution (prepared each day, containing NaCl 149.2 mM, KCl 2.7 mM, NaHCO\(_3\) 11.9 mM, glucose 5.5 mM, CaCl\(_2\) 1.8 mM, MgCl\(_2\) 0.5 mM, NaH\(_2\)PO\(_4\) 0.4 mM). The lung parenchyma was cut parallel to the peripheral margins, yielding four to eight strips, each having a size of 2×2×20 mm and a weight of approximately 60 mg. The parenchymal strips were set up at a resting tension of 4.0 mN in 5 ml organ baths filled with Tyrode's solution, bubbled with carbogen gas (6.5% CO\(_2\) in O\(_2\)) to keep a pH of 7.4 at 37°C. Changes in smooth muscle tension, contractions and relaxations, were recorded via isometric force-displacement transducers connected to a Grass polygraph. After an equilibration period of 90 min and washes each 15 min, histamine was added as a control of the parenchymal strip reactivity. Preparations displaying contraction responses less than 1.0 mN to 30 µM of histamine were excluded from further experiments. Another wash and equilibration period between histamine and treatment period was performed. All antagonists were given 15 min before the challenges. For study the effect of different agonists, the parenchymal strip was exposed to cumulative concentrations. To study the relaxation the parenchyma was pre-contracted with 10 nM of LTD\(_4\) generating a 50% contraction. To study the allergic early phase reaction, ovalbumin was added as cumulative
challenge of increasing concentrations every 10 min without changing bath fluid. Maximum
contractions of the preparation were determined with histamine (1 mM), acetylcholine (1
mM) and potassium chloride (KCl; 50 mM) at the end of each experiment, and other
responses were expressed as percent of maximum contractions.

2.3. Measurements of released mediators with enzyme immunoassays
A 1 mL aliquot of organ bath fluid was collected from each organ bath and immediately
frozen at -20°C. The samples were taken at the end of the equilibration period to obtain basal
mediator release from the tissue and at the obtained contractile plateau after challenge with
ovalbumin 1000 ng/ml. Enzyme immunoassay (EIA) analyses of the prostanoids TXA₂ and
PGD₂ were performed according to the manufacturer’s instructions. TXA₂ was measured as
the stable metabolite TXB₂. PGD₂ was measured as PGD₂-mox. The assay detection limits in
the bath fluid levels were 7.8 pg/ml. The EIA specificity for the different mediators to
interfere with each other was less than 0.01%, with the exception of the EIA kit for TXB₂ that
cross reacted with PGD₂ (0.53%).

2.4. Precision-cut lung slices
Guinea pig precision-cut lung slices were prepared as previously described (Ressmeyer et al.,
2006). Briefly, the lung was filled through the trachea with a low melting-point agarose
solution (0.75%) containing salbutamol (1 mM). Lung tissue cores were prepared and cut into
220-mm-thick slices with a Krumdieck tissue slicer (Alabama Research and Development,
Munford, AL, USA). Tissue slices were incubated at 37°C in a humid atmosphere in minimal
essential medium supplemented with sodium pyruvate, amino acids, vitamins and glutamine.
The medium was changed on a regular basis during four hours in order to remove the agarose
and cell debris from the tissue. Salbutamol was added to the medium during the first three
The slices were then imaged using an analogue (JAI 2040; JAI Pulnix, Alzenau, Germany) or digital camera (IRB640; Visitron Systems, Munich, Germany). For measurements, slices with comparable airway and vessel size were selected.

Bronchoconstriction or vasoconstriction was expressed as airway/vessel area as the percentage of the initial area. A control image was taken before cumulative addition of U46619 or PGD₂ and frames were recorded every 30 sec for 20 min.

2.5. Data analysis and statistical procedures

All data are presented as mean ± standard error of the mean (S.E.M.). Statistical analyses were made for paired and unpaired observations by Student's t-test or analyses of variances (ANOVA) followed by the post hoc tests Bonferroni's t-test. A P-value of less than 0.05 was considered significant. To provide estimates of maximal effect (E_{max}), midpoint location (\text{pEC}_{50}) and Hill slope (n_{H}), agonist concentration-effect curve data from individual tissues were fitted to the Hill equation using an iterative, least square method (GraphPad Prism, San Diego, USA). For the Schild plot analysis, the concentration-response curves with antagonists were set at a global shared maximum assuming competitive antagonism. If the value of the slope was found not to be significantly different from unity a second fit was performed for the calculation of pK_B values with the slope constrained to unity.

2.6. Drugs and chemical reagents

NaCl, KCl, CaCl₂, MgSO₄, NaHCO₃, KH₂PO₄ and glucose were obtained from VWR International (West Chester, Pennsylvania, USA). Histamine dihydrochloride, acetylcholine, ovalbumin (chicken egg albumin, grade II), agarose, salbutamol, dimethylsulfoxid (DMSO) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). 3R-[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (BAYu3405,
Ramatroban) was purchased from Bayer AG (Wuppertal, Germany). PGD$_2$, (4S)-(3-[(3R,S)-
3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid (BW245C), LTD$_4$, 
9,11-dideoxy-9α,11α-methanoepoxy PGF$_{2\alpha}$ (U46619), PGF$_{2\alpha}$, [1S-[1α,2α(Z),3α,4α]-7-[3-[(2-
[(phenylamino)carbonyl]hydrazino)methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid 
(SQ-29548), 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-4-
imidazolidineheptanoic acid (BWA868C), 9α,11β-PGF$_2$ and 13,14-dihydro-15-keto (DK)-
PGD$_2$ were bought from Cayman Chemical (Ann Arbor, MI, USA). LTD$_4$ was from Cascade 
Biochemicals Ltd. (Reading, UK). The EIA kits for TXB$_2$ and PGD$_2$-mox were obtained from 
Cayman Chemicals (Ann Arbor, Michigan, USA). Stock solutions of 1 mM LTD$_4$ and 
prostanoids were dissolved in 50% ethanol-water and then diluted in 20% ethanol-water. 
Ovalbumin was dissolved in 0.9% NaCl. The other drugs were dissolved and diluted in 
Tyrode's solution or millipure water. Dilutions of drugs were freshly made from the stocks for 
each experiment. The drugs were present in the organ bath fluid during the remaining 
experiment. 0.1% DMSO was added as a control and did not influence the baseline or 
cumulative contractions to ovalbumin.
3. Results

3.1. The TP receptor is the main contractile receptor for PGD$_2$, TXA$_2$ and PGF$_{2\alpha}$

PGD$_2$ induced concentration-dependent contractions in the lung parenchyma (Fig. 1A and B). The contraction (79.8 ± 8.5%), obtained at the highest concentration used (100 µM), was according to the non-linear regression analysis not the maximal effect. The inability of PGD$_2$ to reach the maximum capacity of the tissue contrasted to U46619 (Fig. 1C and D), which induced a contraction reaching similar or higher maximum effect as the high concentrations of histamine, acetylcholine and potassium chloride used as the reference at the end of each experiment (108 ± 4.6%) and with a 30-fold greater potency than PGD$_2$ ($pEC_{50}$: 6.68 ± 0.24 and 5.14 ± 0.22, respectively). However, the concentration-response curves for both PGD$_2$ and U44619 were markedly shallow with Hill slopes significantly below 1 (0.58 ± 0.04 and 0.53 ± 0.05).

When preparations were treated with the competitive TP receptor antagonist SQ-29548, the concentration-response curve to PGD$_2$ was shifted to the right (Fig. 1A). Pretreatment with 0.1 or 1 µM of SQ-29548 gave rise to significantly different $pEC_{50}$ values (4.7 ± 0.1 and 4.2 ± 0.1, respectively) compared to control (5.4 ± 0.3; table 1). At these concentrations of SQ-29548, the Hill slope was significantly higher than for the control. Further experiments with the combined TP and DP$_2$ receptor antagonist BAYu3405 (Fig. 1B) also produced concentration-dependent rightward shifts of the PGD$_2$ induced concentration-response curve. Preparations treated with 0.1 or 1 µM BAYu3405 displayed significantly different $pEC_{50}$ values (4.3 ± 0.1 and 4.0 ± 0.2, respectively) compared to controls (5.2 ± 0.2; table 1).

In preparations pre-treated with 0.1 or 1 µM SQ-29548, U46619 displayed a concentration-dependent shift of the concentration-response curve and the $pEC_{50}$ values (6.0 ± 0.2 and 5.3 ± 0.1).
0.2, respectively) were significantly lower than control preparations (6.8 ± 0.2; Fig. 1C). When BAYu3405 was used as TP receptor antagonist, the same pattern was shown again with significantly lower pEC$_{50}$ values for 0.1 or 1 µM BAYu3405 (5.4 ± 0.1 and 5.0 ± 0.1, respectively), compared to control (7.2 ± 0.4; Fig. 1D). To quantify the antagonistic capacity for SQ-29548 and BAYu3405, Schild plot analysis was performed, assuming that the agonist curves reached the similar maximum and ignoring the absence of parallel shifts. Although the antagonists showed a linear regression statistically not deviating from unity it was a tendency for lower Schild slopes for both SQ-29548 (0.89 ± 0.08 for PGD$_2$; P = 0.250; and 0.85 ± 0.18 for U46619; P = 0.521) and BAYu3405 (0.71 ± 0.25 for PGD$_2$; P = 0.375; and 0.84 ± 0.13 for U46619; P = 0.364). The pK$_B$ values for the experiments with SQ-2954 rendered a 10-fold differences between PGD$_2$ and U46619 (7.14 ± 0.08 and 8.17 ± 0.18, respectively) whereas no significant difference was seen in the experiments with BAYu3405 (7.82 ± 0.15 and 7.60 ± 0.16 for PGD$_2$ and U46619, respectively).

To test if the difference between PGD$_2$ and U46619 could relate to metabolism of PGD$_2$, into a compound activating other receptors, the early PGD$_2$ metabolite 9α,11β-PGF$_2$ was studied. 9α,11β-PGF$_2$ yielded a weaker response than both U46619 and PGD$_2$, reaching only about 30% of the maximum contraction (Fig. 2A). The low efficacy of 9α,11β-PGF$_2$ did not make it meaningful to calculate pEC$_{50}$ values. Since there is structural similarity between 9α,11β-PGF$_2$ and the FP receptor agonist PGF$_{2\alpha}$ (Komoto et al., 2004), PGF$_{2\alpha}$ may also be involved in contractions mediated by PGD$_2$ and its metabolites. The effect of PGF$_{2\alpha}$ was almost identical to the effect of its stereoisomer 9α,11β-PGF$_2$ (Fig. 2B). Pretreatment with the TP receptor antagonist SQ-29548 significantly abolished the contractions induced by 9α,11β-PGF$_2$ (P < 0.001) (Fig. 2A) and PGF$_{2\alpha}$ (P < 0.001) (Fig. 2B), indicating that PGF$_{2\alpha}$ acted as a TP receptor agonist in the guinea pig peripheral lung preparation.
3.2. *The DP*$_1$ *receptor induce a weak relaxation of peripheral lung tissue*

The DP$_1$ receptor has been described to mediate relaxation of vascular and bronchial SMCs (Norel, 2007). Therefore, it was investigated if the DP$_1$ receptor may mediate relaxation of peripheral lung tissue. Lung strips were treated with cumulative concentrations of the DP$_1$ receptor agonist BW245C after pre-contraction with 10 nM of LTD$_4$. The pre-contracted strips relaxed at the highest concentration of BW245C (10 µM) (Fig 3A). Based on these results, experiments with the DP$_1$ receptor antagonist BWA868C (0.1 and 1 µM) were performed with the hypothesis that inhibition of the DP$_1$ receptor should enhance the PGD$_2$ induced contractions. However, the BWA868C treated preparations yielded pEC$_{50}$ values for PGD$_2$ that were not significantly different from controls (Fig. 3B and table 2).

3.3. *The DP*$_2$ *receptor induce neither contraction nor relaxation*

Since BAYu3405 is both a TP and DP$_2$ receptor antagonist, the DP$_2$ receptor mediated response in the parenchyma was investigated. Cumulative concentrations of the DP$_2$ receptor agonist DK-PGD$_2$ were added to the lung preparations both before and after pre-contraction with LTD$_4$. DK-PGD$_2$ up to 10 µM generated neither significant contraction nor relaxation of the peripheral lung tissue (n=5, data not shown).

3.4. *The effects of PGD*$_2$ *and U46619 in airways and pulmonary vessels in precision-cut lung slices*

Since the lung parenchyma preparation consists of both airways and vessels, precision cut lung slices were examined to study the contractile effect of PGD$_2$ and U46619 in peripheral airways and pulmonary arteries and veins. Indeed, PGD$_2$ induced contractile effects in airways (pEC$_{50}$: 6.8 ± 0.1) as well as both pulmonary veins (pEC$_{50}$: 7.2 ± 0.2) and arteries
(pEC<sub>50</sub>: 6.0 ± 0.2; Fig. 4A). U46619 induced similar strong contractile responses but was significantly more potent in airways (pEC<sub>50</sub>: 8.9 ± 0.2), veins (pEC<sub>50</sub>: 9.2 ± 0.2) and arteries (pEC<sub>50</sub>: 8.1± 0.2) in the lung parenchymal preparation (Fig. 4B).

3.5. Role of prostanoids on antigen-induced contractions

Since the contractile effect of both PGD<sub>2</sub> and U46619 was mediated through the TP receptor, experiments with SQ-29548 were performed to study the significance of this receptor in the early allergic reaction. Thus, cumulative challenge with ovalbumin on parenchymal strips from sensitized guinea pigs caused a concentration-dependent contraction that reached about 60-70% of the maximum contraction. Pre-treatment with SQ-29548 partly decreased the ovalbumin-induced contraction (P < 0.01). Analysis of the bath fluid after challenge with ovalbumin (1 µg/mL) showed that TXB<sub>2</sub> (1021 ± 325 fmol/g; n=6) was released in 20-fold higher concentration than PGD<sub>2</sub> (53 ± 6 fmol/g; n=6). Synthesis before ovalbumin stimulation was 61 ± 51 fmol/g for TXB<sub>2</sub> and not detectable for PGD<sub>2</sub>. 
4. Discussion

It was found that the predominant effect of PGD$_2$ in the peripheral lung is a contractile effect which is mediated through activation of TP receptors situated on airways as well as arteries and veins in the parenchymal lung tissue. A minor relaxant effect was found to be mediated through the DP$_1$ receptor and no effect was found to be mediated through the DP$_2$ in the present study. When inducing ovalbumin activation of sensitized parenchymal strips, both TXA$_2$ and PGD$_2$ were released. Ovalbumin also induced contractions that were partly mediated through activation of the TP receptor. Thus, a TP receptor antagonist can be useful to block the contractile action of TXA$_2$ and PGD$_2$ in allergic reactions in the airways (Beasley et al., 1989).

PGD$_2$ and the TP receptor agonist U46619 induced both concentration-response curves with Hill slopes clearly lower than 1, indicating a complexity in the contractile action. One possibility that could explain these shallow curves is if the effects were due to action through more than one receptor. However, since the selective TP (SQ-29548 (Abramovitz et al., 2000); and the dual TP/DP$_2$ (BAY u3405 (Sugimoto et al., 2005)) receptor antagonists caused right-ward shifts of the concentration-response curve to PGD$_2$, this indicated, as in line with previous observations (Hamid-Bloomfield et al., 1990; McKenniff et al., 1991), that the TP receptor mediates the main part of the PGD$_2$-induced contraction. As U46619 induced both stronger contraction and was more potent than PGD$_2$, the data indicated, in accordance with the much lower affinity for PGD$_2$ to the TP receptor (Abramovitz et al., 2000), that the responses were mediated through the TP receptor. On the other hand, the curves for the antagonist were not shifted in parallel. Although fully concentration-response curves of PGD$_2$ were not able to obtain due to the high concentration needed, a clear trend to increased Hill slope with increasing concentration of antagonists was found for both the agonists, mutually
with SQ-29548 and BAY u3405. It is possible that the reason for this increase is due to that both PGD$_2$ and U46619 have shown the capacity to bind to almost all prostanoid receptors (Abramovitz et al., 2000). Thus, at the higher concentrations of the agonists used for the antagonist experiments, the activation of the TP receptor simultaneously with one or more prostanoid receptors cause an additional or a synergistic effect.

Although the Schild plot slopes did not significantly deviate from unity there was a trend to lower slope values, which may be due to actions of more than one receptor, especially at the higher concentrations of the agonists. Also the discrepancy of the pK$_B$ values for SQ-29548 and not BAY u3405 between the agonists can indicate that another receptor than the TP receptor is activated. The pK$_B$ values for BAY u3405 (7.82 and 7.60 for PGD$_2$ and U46619, respectively) are in line with presented earlier in guinea pig lung strips (7.7 with U46619 as agonist; (Norman et al., 1992)) whereas the pK$_B$ values for SQ-29548 was 10 fold lower for BAY u3405 (7.14) than for U46619 (8.17) as agonists (range from 7.7 to 8.7 in guinea pig; (Dube et al., 1992; Norman et al., 1992). Since it has been shown that U46619 do not activate the DP$_2$ receptor (Monneret et al., 2001), the lower pK$_B$ value for SQ-29548 from the PGD$_2$ experiments can be due to activation of DP$_2$ receptors. However, as described in this study, a negligible effect is shown when this receptor is selectively activated. Thus, from these experiments the reason for the difference of the pK$_B$ values for SQ-29548 cannot be completely concluded. Taking all these complexities of the actions of the agonists both in absence and presence of antagonism in consideration, the clear antagonism with both these known TP receptor antagonists indicates that the main action of PGD$_2$ goes through the TP receptor.
The major PGD$_2$ metabolite, 9α,11β-PGF$_2$, induced a weak contraction of the peripheral lung that was blocked by SQ-29548 indicating that the breakdown of PGD$_2$ in this assay do not cause activation of any further receptor then PGD$_2$ by itself. PGF$_{2\alpha}$ is a stereoisomer to 9α,11β-PGF$_2$ and closely structurally related to PGD$_2$ (Sandig et al., 2006). Thus, one possibility was that PGD$_2$ also acted through FP receptors (Kiriyma et al., 1997). Since there are no specific receptor antagonists available for the FP receptor we chose to investigate how the response to PGF$_{2\alpha}$ could be blocked by SQ-29548. However, as the effect of PGF$_{2\alpha}$ was abolished by SQ-29548 it is unlikely that PGD$_2$ mediate any major effect through the FP receptor. Altogether, these data implicate that PGF$_{2\alpha}$, which along with PGD$_2$ has been shown to be released after antigen challenge in guinea pig lung (Dawson et al., 1976), also is part of the TP receptor mediated constriction of the peripheral lung.

The DP$_1$ receptor has been shown to mediate relaxation of the bronchioles in response to PGD$_2$ and may thus serve as protection in a situation of bronchoconstriction (Norel et al., 1999). Studies have also shown that rabbit jugular vein preparations treated with the DP$_1$ receptor agonist BW245C relaxed concentration-dependently (Lydford et al., 1996). Nevertheless, the DP$_1$ receptor agonist only weakly relaxed the parenchymal lung tissue in the present study. Furthermore, the DP$_1$ receptor antagonist BWA868C did not affect the PGD$_2$ induced contractions. Since the DP$_2$ receptor agonist did not induce contractions or relaxations in this lung preparation, this point towards that the main action for PGD$_2$ on airway inflammation is the known induction of chemotaxis of eosinophils, basophils and Th2 cells in guinea pigs (Liu et al., 2005) rather than direct responses on the airway smooth muscle.

During the control situation, both agonists induced shallow concentration-response curves in the parenchymal strips. Except for activation on more than one receptor, these shallow curves
can be due to the action of several smooth muscle components, such as small airways and vessels (Evans and Adler, 1981), that not react with similar potencies and maximal effects. In the precision-cut lung slice experiments, the potency difference between PGD$_2$ and U44619 of the three studied components was similar as in the parenchymal strips (approximately 100-fold) indicating similar contractile actions for the agonists during the control situation.

However, a clear difference was obtained between the components, especially the pulmonary arteries compared to the airways and pulmonary veins with a both lower potency and maximal effect in the arteries, suggesting that this is the reason for the shallow control curves for both PGD$_2$ and U46619. Actually, it is indicated that not only airways and vessels but also pleural cells, alveolar ducts and interstitial cells are activated by TP receptor agonists (Wong et al., 1992). Thus, it is possible that these more peripheral located contractile units, which not easily can be measured in precision-cut lung slices, together with the airways and vessels are activated in a serial manner causing the described shallow concentration-response curves for the two agonists.

Allergen-challenge with ovalbumin showed that both PGD$_2$ and TXA$_2$, the latter measured as TXB$_2$, are released from the distal lung tissue and may be important mediators of the allergen-induced bronchoconstriction in the peripheral lung. Previous studies in this model have shown that also histamine, leukotrienes and PGE$_2$ are generated after ovalbumin stimulation (Larsson et al., 2009). The 20-fold higher level of TXB$_2$ in this study is similar to the levels which have been seen in effluent from ovalbumin exposed isolated perfused and ventilated guinea pig lung (Selg et al., 2008). That TXA$_2$ also is released from mast cells has been shown in studies of the human mast cell line HMC-1 (Macchia et al., 1995). However, human purified sinus mast cells showed a 10-fold higher level of PGD$_2$ than TXB$_2$ after IgE stimulation (Mita et al., 1999) suggesting that clear species or anatomical differences exist.
Previously it has been shown that anti-histamine or 5-LO inhibitor alone has no inhibitory effect on the antigen-induced contraction in guinea pig lung parenchyma (Jonsson and Dahlen, 1994; Larsson et al., 2007). Furthermore, it has been shown that the allergen induced contraction in the peripheral lung of the guinea pig needs to be antagonised or inhibited via several mediator pathways in order to significantly attenuate the contraction (Larsson et al., 2007; Ressmeyer et al., 2006). However, in the present study we found that the TP receptor antagonist significantly inhibited part of the ovalbumin-induced contractions. Thus, the experimental results suggest that TP receptors mediate a significant component of the allergen-induced contractions in this model of the peripheral lung. The explanation, indicated by our findings, may be that several COX-products released by the antigen-challenge (PGD$_2$, TXA$_2$ and PGF$_{2\alpha}$; (Dawson et al., 1976) all act on TP receptors.

The present study highlights that the parenchymal constriction induced by PGD$_2$ should be attributed to its properties as a TP receptor agonist. Even though PGD$_2$ may have minor role as an agonist in the allergen-induced contraction in guinea pigs, since it is both released in lower amount and have lesser effect than TXA$_2$, the role in human may be of great importance due to the high amount of mast cell release (Mita et al., 1999). Accordingly, the contractile effect of PGD$_2$ in human airways has also been shown to be antagonized by BAY u3405 (Magnussen et al., 1992), which can be important to bear in mind when considering the treatment of early asthmatic responses. Furthermore, the results here are consistent with other studies showing that the allergen response needs to be antagonised or inhibited via several mechanisms to attenuate the contraction (Jonsson and Dahlen, 1994; Roquet et al., 1997; Selg et al., 2009). In this concept, therapy with TP receptor antagonists should be considered as one important component to reduce early asthmatic responses in patients.
Acknowledgement

We would like to express our gratitude to Margareta Andersson for skillful technical assistance and we would like to thank Swedish Research Council in Medicine and Health, Swedish Heart and Lung foundation, Vinnova Chronic inflammation - diagnostic and therapy (CIDaT), the Crafoord Foundation, the Stockholm County Council Research Funds (ALF), Karolinska Institutet, the Tore Nilsson Foundation and the Swedish Society of Medicine for financial support.


Canning, B.J., Chou, Y., 2008. Using guinea pigs in studies relevant to asthma and COPD.


Figure legends

**Fig. 1.** Contractions induced by cumulative concentrations of (A and B) PGD$_2$ and (C and D) TP receptor agonist U46619 in guinea pig lung parenchymal strips. The experiments were performed in absence or presence of (A and C) the TP receptor antagonists SQ-29548 or (B and D) BAY u3405 (n=5-6). Data are presented as mean ± S.E.M..

**Fig. 2.** Contractions induced by cumulative concentrations of (A) 9α,11β-PGF$_2$ and (B) PGF$_{2α}$ in guinea pig lung parenchymal strips. The experiments were performed in absence or presence of 1µM of the TP receptor antagonist SQ-29548 (n=5). Data are presented as mean ± S.E.M..

**Fig. 3.** Studies of the DP$_1$ receptor in guinea pig lung parenchymal strips. (A) Effect of cumulative concentrations of the DP$_1$ receptor agonist BW245C after precontraction with LTD$_4$ 10 nM and (B) effect of the DP$_1$ receptor antagonist BWA868C on PGD$_2$ induced contractions (n=5). Data are presented as mean ± S.E.M..

**Fig. 4.** Contractile responses to (A) PGD$_2$ and (B) the TP receptor agonist U46619 in airway and, pulmonary artery and vein in guinea pig precision cut lung slices. Data presented as % change of initial luminal area (n=4). Data are presented as mean ± S.E.M..

**Fig. 5.** Effect of the TP receptor antagonist SQ-29548 on cumulative doses of ovalbumin (0.001-10 µg/ml) in absence and presence of 1 µM SQ-29548 (n=4) in guinea pig lung parenchymal strips. Data are presented as mean ± S.E.M.
### Table 1: Effects of the TP receptor antagonists on PGD₂ and U46619 induced contractions

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>Emax</th>
<th>pEC50</th>
<th>Hill slope</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGD₂ (Control)</td>
<td>6</td>
<td>65.2±4.8</td>
<td>5.4±0.3</td>
<td>0.6±0.0</td>
</tr>
<tr>
<td>PGD₂ + SQ-29548 0.01µM</td>
<td>6</td>
<td>78.9±0.7</td>
<td>4.9±0.1</td>
<td>0.6±0.0</td>
</tr>
<tr>
<td>PGD₂ + SQ-29548 0.1µM</td>
<td>6</td>
<td>72.5±5.2</td>
<td>4.7±0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.9±0.1&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>PGD₂ + SQ-29548 1µM</td>
<td>6</td>
<td>50.1±7.1</td>
<td>4.2±0.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.7±0.1&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>PGD₂ (Control)</td>
<td>5</td>
<td>75.7±3.5</td>
<td>5.2±0.2</td>
<td>0.6±0.0</td>
</tr>
<tr>
<td>PGD₂ + BAYu3405 0.1µM</td>
<td>5</td>
<td>64.7±8.2</td>
<td>4.3±0.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.4±0.2&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>PGD₂ + BAYu3405 1µM</td>
<td>5</td>
<td>49.2±15.1</td>
<td>4.0±0.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.9±0.1&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>U46619 (Control)</td>
<td>6</td>
<td>99.1±0.9</td>
<td>6.8±0.2</td>
<td>0.6±0.1</td>
</tr>
<tr>
<td>U46619 + SQ-29548 0.01µM</td>
<td>5</td>
<td>99.1±1.0</td>
<td>6.6±0.2</td>
<td>0.7±0.1</td>
</tr>
<tr>
<td>U46619 + SQ-29548 0.1µM</td>
<td>5</td>
<td>100.0±0.0</td>
<td>6.0±0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.8±0.1</td>
</tr>
<tr>
<td>U46619 + SQ-29548 1µM</td>
<td>5</td>
<td>100.0±0.0</td>
<td>5.3±0.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.6±0.3&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>U46619 (Control)</td>
<td>6</td>
<td>98.6±1.2</td>
<td>7.2±0.4</td>
<td>0.5±0.1</td>
</tr>
<tr>
<td>U46619 + BAYu3405 0.01µM</td>
<td>5</td>
<td>99.8±0.2</td>
<td>6.5±0.2</td>
<td>0.7±0.2</td>
</tr>
<tr>
<td>U46619 + BAYu3405 0.1µM</td>
<td>5</td>
<td>100.0±0.0</td>
<td>5.4±0.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.1±0.2</td>
</tr>
<tr>
<td>U46619 + BAYu3405 1µM</td>
<td>5</td>
<td>97.9±2.1</td>
<td>5.0±0.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.6±0.2&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Calculations of Emax, pEC50 and Hill slope presented as mean ± S.E.M.. Significant differences from the agonists (controls) are indicated as <sup>a</sup>P<0.05, <sup>b</sup>P<0.01 or <sup>c</sup>P<0.001.
Table 2. Effects of the DP$_1$ receptor antagonist on PGD$_2$ induced contractions

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>Emax</th>
<th>pEC$_{50}$</th>
<th>Hill slope</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGD$_2$ (Control)</td>
<td>5</td>
<td>83.8 ± 6.4</td>
<td>4.6 ± 0.3</td>
<td>0.4 ± 0.0</td>
</tr>
<tr>
<td>PGD$_2$ + BWA868C 0.1µM</td>
<td>5</td>
<td>81.5 ± 5.9</td>
<td>4.9 ± 0.1</td>
<td>0.5 ± 0.1</td>
</tr>
<tr>
<td>PGD$_2$ + BWA868C 1µM</td>
<td>5</td>
<td>76.9 ± 7.4</td>
<td>5.0 ± 0.3</td>
<td>0.5 ± 0.1</td>
</tr>
</tbody>
</table>

Calculations for Emax, pEC$_{50}$ and Hill slope are presented as mean ± S.E.M..
Figure 1

(A) Control
- SQ-29548 0.01 μM
- SQ-29548 0.1 μM
- SQ-29548 1 μM

(B) Control
- BAYu3405 0.1 μM
- BAYu3405 1 μM

(C) Control
- SQ-29548 0.01 μM
- SQ-29548 0.1 μM
- SQ-29548 1 μM

(D) Control
- BAYu3405 0.01 μM
- BAYu3405 0.1 μM
- BAYu3405 1 μM

[Graphs showing the effect of various concentrations of PGD₂ and U46619 on the contraction of tissues.]

Contraction (% of maximum)
log [PGD₂] M

Contraction (% of maximum)
log [U46619] M
Figure 2

A

B

- Log [9α,11β-PGF2α] M

- Log [PGF2α] M

- Contraction (% of maximum)

- Control

- SQ-29548 1 μM

- Contraction (% of maximum)
Figure 3

A

B

![Graph A](image1)

![Graph B](image2)
Figure 4

**A**

![Graph showing luminal area (% of initial area) vs. Log [PGD₂] M](image)
- Circles: Airway
- Squares: Artery
- Triangles: Vein

**B**

![Graph showing luminal area (% of initial area) vs. Log [U46619] M](image)
- Circles: Airway
- Squares: Artery
- Triangles: Vein
Figure 5

- O Control
- □ SQ-29548 1 μM

Contraction (% of maximum) vs. log [OVA] g/mL

Values are means ± SEM.